RT Journal
A1 Matava, Matthew J.
T1 Platelet-Rich Plasma: The Next Big Thing?Commentary on an article by Ujash Sheth, BHSc, et al.: “Efficacy of Autologous Platelet-Rich Plasma Use for Orthopaedic Indications: A Meta-Analysis”
JF The Journal of Bone & Joint Surgery
JO The Journal of Bone & Joint Surgery
YR 2012
FD February 15
VO 94
IS 4
SP e25 1
OP 2
DO 10.2106/JBJS.K.01423
UL http://dx.doi.org/10.2106/JBJS.K.01423
AB 
Autologous blood concentrates, one of which is platelet-rich plasma, have been becoming more popular as a result of the increasing attention that these products have received in the mainstream media following their use by high-profile athletes. Platelet-rich plasma has been utilized for a number of musculoskeletal conditions despite a relative lack of rigorous supportive data. Thus, there is a growing debate regarding the clinical efficacy of this treatment regimen. Several uncontrolled studies have shown beneficial effects for a variety of indications. However, the results of controlled trials comparing platelet-rich plasma with standard therapies have not been as definitive. Despite this relative lack of robust evidence, the market for platelet-rich plasma is expected to be worth $126 million by 20161.